Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

BACKGROUND: Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination. METHODS: This is a prospective, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudewijns, Steve, Bloemendal, Martine, de Haas, Nienke, Westdorp, Harm, Bol, Kalijn F., Schreibelt, Gerty, Aarntzen, Erik H. J. G., Lesterhuis, W. Joost, Gorris, Mark A. J., Croockewit, Alexandra, van der Woude, Lieke L., van Rossum, Michelle M., Welzen, Marieke, de Goede, Anna, Hato, Stanleyson V., van der Graaf, Winette T. A., Punt, Cornelis J. A., Koornstra, Rutger H. T., Gerritsen, Winald R., Figdor, Carl G., de Vries, I. Jolanda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044256/
https://www.ncbi.nlm.nih.gov/pubmed/31980913
http://dx.doi.org/10.1007/s00262-019-02466-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044256/
https://www.ncbi.nlm.nih.gov/pubmed/31980913
http://dx.doi.org/10.1007/s00262-019-02466-x

Ejemplares similares